{"disease":{"id":"severe-active-rheumatoid-arthritis","name":"severe active rheumatoid arthritis"},"drugs":{"marketed":[{"drug_id":"upadacitinib","indication_name":"Moderately to severely active rheumatoid arthritis in adults with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06048224","title":"Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":669,"lead_sponsor_name":"Zhejiang Hisun Pharmaceutical Co. Ltd.","has_results":false},{"nct_id":"NCT03522415","title":"Study of Safety and Efficacy of HLX01+MTX in Patients With Rheumatoid Arthritis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":275,"lead_sponsor_name":"Shanghai Henlius Biotech","has_results":false},{"nct_id":"NCT06738719","title":"A Phase 3 Study to Evaluate Efficacy & Safety of Subcutaneous CT-P13 in Patients With Moderate to Severe Active Rheumatoid Arthritis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":192,"lead_sponsor_name":"Celltrion","has_results":false},{"nct_id":"NCT03357471","title":"Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"UCB Biopharma S.P.R.L.","has_results":true}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}